Sanofi's Intanza/IDflu cleared in Europe

9 March 2009

Sanofi Pasteur, the vaccines division of French drug major  Sanofi-Aventis, says that its seasonal influenza vaccine Intanza/IDflu  has been approved in Europe.

According to Sanofi, which is the world's third-largest drugmaker by  sales, the convenience and the ease of administration of the product  should help improve the coverage rate in Europe.

The agent will be used for the prevention of seasonal influenza in both  the adult (aged 18 and over) and elderly (aged 60 and over) populations.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight